Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ): Is This Pharmaceutical Giant About To Lose Its Cornerstone Drug?

Page 1 of 2

What’s the worst nightmare of all pharmaceutical companies? Generics. They might as well be the grim reaper in the eyes of the brand-name pharmaceuticals. Generics completely destroy the pricing power and monopoly one company possesses on a particular drug, costing that particular company billions in lost revenue. Just one example of the devastating effects generics have on the original patent holding company is displayed in the case of Lipitor, a Pfizer Inc. (NYSE:PFE) drug whose patent expired in 2011. Revenue produced by the drug for Pfizer dropped 59% from 2011 to 2012. So when a generic manufacturer receives support from any health organization, it can literally be a billion-dollar game changer.

On June 28, the European Medicines Agency ruled that regulators should give Hospira, Inc. (NYSE:HSP) and South Korean drug maker Celltrion approval to market their version of the drug for the same medical conditions for which Remicade is marketed.

Johnson & Johnson (NYSE:JNJ)

Remicade is a cornerstone drug for Johnson & Johnson (NYSE:JNJ), generating $6.14 billion in revenue for the company in 2012, the largest drug for the company in terms of revenue, accounting for 9.13% of overall company revenue. The generic version being developed by Hospira and Celltrion will be the first biosimilar versions of a monoclonal antibody to be recommended in a major market.

Hospira and Celltrion both rallied extensively after the news of the EMA’s decision was released. Johnson & Johnson (NYSE:JNJappears unaffected, only marginally lower on an overall weak market day.

Others will be affected

The target conditions treated by Remicade – Crohn’s disease, ulcerative colitis, rheumatoid and psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis – are also targeted by similar drugs in the subsector, including Humira, Celebrex, and a host of other brand-name drugs. The potential of a generic breed of Remicade may also destroy the pricing power of these other drugs, as all drugs targeting a particular condition compete with each other for customers.

Companies carrying a particular concern are AbbVie Inc (NYSE:ABBV) and Pfizer. AbbVie’s cornerstone drug, Humira, produced $9.26 billion in revenue in the 2012 year. That’s 50.38% of overall company revenue, representing a major dependence on a single drug. Humira treats rheumatoid and psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis; all of which are also treated by Remicade and Hospira’s generic version of the drug. Humira’s patent is set to expire in 2016. Pfizer’s play on this particular market is Celebrex, which treats arthritis pain and inflammation as well as acute pain. In 2012, Celebrex generated $2.72 billion in revenue, representing 4.61% of overall company revenue. Pfizer’s patent on Celebrex is set to expire in December 2015, and was recently extended from May 2014 to the current date.

Page 1 of 2
Loading...